PerpEquities

Equity

Is Arrowhead Pharmaceuticals, Inc. (ARWR) tradable as a perp? Not right now

Arrowhead Pharmaceuticals is a biopharmaceutical company in Pasadena, California that develops RNA interference (RNAi) therapeutics for complex diseases.

Currently not listed on any perp exchange

ARWR traded as a perpetual on MEXC until October 23, 2026. No venue lists it at the moment; we keep tracking it, and with the next listing this page becomes a full market page again. Until then: fundamentals below and tradable alternatives.

Similar stocks already tradable as perps
NCLHMGMTUCCELHAMKRSNAP

Price chart

Interactive TradingView chart

TradingView symbol NASDAQ:ARWR

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-08-04 · next report 2026-11-12 · Updated 1h ago
All financials →

Valuation & key figures

Market cap
$8.2B
Updated 1h ago
Revenue
$669.5M
Trailing 12 months
Revenue growth
-60%
Next fiscal year
Profit margin
-47.8%
P/E
-26.0
Peer P/E 12.7
P/S
12.3
Peer P/E
12.7
Similar listed perps
Free cash flow
-$75.1M
Trailing 12 months
Net income
-$320M
Trailing 12 months
Revenue estimate
$330.1M
Next fiscal year
Earnings
2026-11-12
Revenue est. $61.2M · Updated 1h ago
Dividend
-
Revenue (TTM)$669M+16.8% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)-33.8%-15.0 pp vs a year agoOperating income -$226M
Net income (TTM)-$320M-115.6% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$75.1M-326.3% vs a year agoCapex $16.1M
Diluted EPS (TTM)-$2.24-72.3% vs a year agoSum of the last 4 quarters
Net cash$738M+294.4% vs a year agoCash + short-term investments - debt
  • Last report (2026-08-04): revenue beat by 70.4%, EPS missed by 6.3%Revenue $75.3M vs $44.2M expected (+70.4%); EPS -$1.36 vs -$1.28 (-6.3%).
  • Revenue growth slowing: 171.0% year on yearQ3 '26 revenue $75.3M, against an average of 5,187.5% over the four quarters before.
  • Operating margin -33.8% (TTM), -15.0 pp on a year agoOperating income grew -109.7% while revenue grew 16.8%.
  • Capex 2.4% of revenue (a year ago 6.9%)$16.1M invested in the last 4 quarters (-59.3% on a year earlier). Free cash flow -$75.1M.

Revenue, operating income and growth

quarterly
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 228 lines Arrowhead Pharmaceuticals, Inc. reported to the SEC

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-3.52$464.2M-44%12
FY 2027-4.86$330.1M-60%13
FY 2028-2.81$666.1M-20%8
FY 2029-0.74$1.1B+38%5
FY 20304.41$2B+146%3
Q3 2026-1.52$61.2M-19%12

Company events

6
2026-11-12Earnings · After market closeActual - / Estimate -1.52-
2026-08-04EarningsActual -1.36 / Estimate -1.28Miss
2026-05-07EarningsActual -0.93 / Estimate -1.09Beat
2026-02-05EarningsActual 0.22 / Estimate 0.6Miss
2025-11-25EarningsActual -0.18 / Estimate -0.11Miss
2025-08-07EarningsActual -1.26 / Estimate -0.94Miss

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
NCLH$8.2B0.89.9+8.2%1MGM$8.2B0.512.2+3.9%2TUC$8.3B5.331.1+16.6%2CELH$8.1B2.635.7+9.4%1AMKR$8.1B1.113.1+8.3%3SNAP$8.4B1.3-53.0-2.3%2CGNX$8B7.133.2+21.5%9GTLB$8B7.6-152.5-5.0%14

Analyst track record

How the analysts covering ARWR have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings100274
Analysts1623
Buy / hold / sell86 / 14 / 0203 / 71 / 0
Upgrades / downgrades / initiations1 / 0 / 51 / 2 / 8
Price targets hit / missed11 / 78 (12%)127 / 113 (53%)
Avg. return after a rating (TipRanks)-27.7%+26.5%
Best / worst call+76.2% / -51.1%+414.0% / -51.1%

After buy calls on this stock: median 21-day move +0.9% vs S&P 500 -0.9% (n = 201)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Jason GerberryBank of America Securities53% hit rate on this stock · 15 targets measuredBuytarget $100Oct 12, 2026
  2. Luca IssiRBC Capital50% hit rate on this stock · 12 targets measuredBuytarget $100Aug 30, 2026
  3. Edward TenthoffPiper Sandler38% hit rate on this stock · 21 targets measuredBuytarget $126Oct 15, 2026

Latest ratings

DateAnalystCallTarget
Nov 5, 2026Patrick TrucchioH.C. WainwrightBuyReiterated$120article ↗
Oct 20, 2026Unknown AnalystUBSBuyInitiated$109article ↗
Oct 20, 2026Unknown AnalystUBSBuyInitiated$109
Oct 15, 2026Brian ChengJ.P. MorganBuyReiterated–article ↗
Oct 15, 2026Edward TenthoffPiper SandlerBuyReiterated$126article ↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$60.00$70.00$80.00$90.00$100$110Dec 25 · Buy 7 · Hold 6 · Sell 0Dec 25Jan 26 · Buy 8 · Hold 5 · Sell 0Feb 26 · Buy 8 · Hold 5 · Sell 0Feb 26Mar 26 · Buy 8 · Hold 4 · Sell 0Apr 26 · Buy 9 · Hold 3 · Sell 0Apr 26May 26 · Buy 10 · Hold 3 · Sell 0Jun 26 · Buy 9 · Hold 3 · Sell 0Jun 26Jul 26 · Buy 10 · Hold 2 · Sell 0Aug 26 · Buy 10 · Hold 2 · Sell 0Aug 26Sep 26 · Buy 11 · Hold 2 · Sell 0Oct 26 · Buy 12 · Hold 2 · Sell 0Oct 26Nov 26 · Buy 12 · Hold 2 · Sell 0Dec 25 · avg. target $54.75Jan 26 · avg. target $71.67Feb 26 · avg. target $71.67Mar 26 · avg. target $81.70Apr 26 · avg. target $85.10May 26 · avg. target $87.91Jun 26 · avg. target $90.00Jul 26 · avg. target $104Aug 26 · avg. target $106Sep 26 · avg. target $103Oct 26 · avg. target $104Nov 26 · avg. target $104Dec 25 · month-end close $66.39Jan 26 · month-end close $69.33Feb 26 · month-end close $63.27Mar 26 · month-end close $62.70Apr 26 · month-end close $73.48May 26 · month-end close $77.91Jun 26 · month-end close $81.51Jul 26 · month-end close $84.65Aug 26 · month-end close $82.39Sep 26 · month-end close $65.45Oct 26 · month-end close $59.90Nov 26 · month-end close $59.90

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 5, 2026 · 100 ratings